We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Biofield Expands Arsenal of Non-Invasive Diagnostic Devices
News

Biofield Expands Arsenal of Non-Invasive Diagnostic Devices

Biofield Expands Arsenal of Non-Invasive Diagnostic Devices
News

Biofield Expands Arsenal of Non-Invasive Diagnostic Devices

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Biofield Expands Arsenal of Non-Invasive Diagnostic Devices"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Biofield Corp. has announced that it has acquired additional products for its portfolio of non-invasive cancer diagnostic products. Specifically, Biofield has acquired the exclusive worldwide distribution rights outside of Belgium, for ValiRx plc’s Human Papilloma Virus (HPV) diagnostic test for cervical cancer as well as for ValioRx’s HyperGenomics™ and Nucleosomic™ cancer diagnostics products.

The Company has also announced that is has opened an office in Bangalore, India where it is has been preparing to begin marketing the oral herpes device pursuant to the exclusive worldwide distribution rights it acquired from NeuroMed, as previously announced.

The company expects to begin marketing the device through a wholly owned Indian subsidiary, via direct web based/internet marketing, retail, wholesale and through physicians and hospitals within the next 30 days.

Shepard G. Bentley, the Company’s Chief Executive Officer, stated: “We are very pleased to be able to add a HPV diagnostic test for cervical cancer as well as ValioRx’s HyperGenomics™ and Nucleosomics™ cancer diagnostics products to our portfolio. When combining these products with those which we acquired pursuant to an exclusive worldwide distribution agreement with NeuroMed Devices, Inc. for the treatment of oral and genital herpes, with our own proprietary BDS, we are extremely well positioned to provide a broad range of non-invasive products and services.”
Advertisement